Ultragenyx Analyst Day Presentation

Key licenses & intellectual property – Commercial products Product CRYSVITAⓇ (XLH, TIO) MEPSEVII® (MPS 7) License Kyowa Kirin Co. (KKC) St. Louis University (Know-How) N/A (IP Owned by Ultragenyx) Baylor Research Institute (BRI) DOJOLVIⓇ (LC-FAOD) N/A (IP Owned by Ultragenyx) Product License EVKEEZA® (HOFH) Regeneron Includes granted U.S. patent term extension 2Includes projected U.S. patent term extension ³Includes projected extension via supplementary protection certificates (SPCs) 20 Confidential and Proprietary US Intellectual Property Rights/Royalties • Anti-FGF23 antibodies and use for treatment of XLH and TIO (2023-2032)¹ Q2W dosing for treatment of FGF23-associated hypophosphatemic disorders (2035) See discussion of KKC license and collaboration in annual report for royalty summary Low single-digit royalty until expiration of orphan drug exclusivity Recombinant human GUS (rhGUS) and use for treatment of MPS7 (2035) Compositions comprising triheptanoin (2025-2029)² Mid single-digit royalty Ultrapure triheptanoin and use in treatment of FAOD (Pending; 2034) EU Intellectual Property Rights/Royalties + Milestones Evkeeza antibody and use for treatment of HOFH (2036)³ Evkeeza antibody in combination with other agents for treatment of HOFH (Pending: 2037) Stabilized formulations of Evkeeza (Pending: 2041) Regeneron supplies product and charges Ultragenyx a transfer price from the low 20% range up to 40% on net sales Ultragenyx to pay up to $63M in potential regulatory and sales milestones ultragenyx

View entire presentation